Page 138 - 《中国药房》2024年20期

[20] STEENBERGEN J，TANAKA S K，MILLER L L，et al. gress of Clinical Microbiology and Infectious Diseases.
In vitro and in vivo activity of omadacycline against two Basel，Switzerland：Congress of the European Society of
biothreat pathogens，Bacillus anthracis and Yersinia pestis Clinical Microbiology and Infection Disease，2016：P1318.
[J]. Antimicrob Agents Chemother，2017，61（5）：e02416- [33] BERG J K，TZANIS E，GARRITY-RYAN L，et al. Phar‐
e02434. macokinetics and safety of omadacycline in subjects with
[21] HONEYMAN L，ISMAIL M，NELSON M L，et al. impaired renal function[J]. Antimicrob Agents Chemother，
Structure-activity relationship of the aminomethylcyclines 2018，62（2）：e02017-e02057.
and the discovery of omadacycline[J]. Antimicrob Agents [34] CORNELY O A，FILE T M，Jr，GARRITY-RYAN L，et al.
Chemother，2015，59（11）：7044-7053. Safety and efficacy of omadacycline for treatment of
[22] YANG W R，MOORE I F，KOTEVA K P，et al. TetX is a community-acquired bacterial pneumonia and acute bacte‐
flavin-dependent monooxygenase conferring resistance to rial skin and skin structure infections in patients with mild-
tetracycline antibiotics[J]. J Biol Chem，2004，279（50）： to-moderate renal impairment[J]. Int J Antimicrob Agents，
52346-52352. 2021，57（2）：106263.
[23] 叶卓幸，汤燕君，何璐茜，等. 四环素类抗生素耐药研究 [35] ZHANEL G G，ESQUIVEL J，ZELENITSKY S，et al.
进展：质粒介导的替加环素耐药机制[J]. 生态毒理学报， Omadacycline：a novel oral and intravenous aminomethyl‐
2022，17（4）：122-140. cycline antibiotic agent[J]. Drugs，2020，80（3）：285-313.
YE Z X，TANG Y J，HE L X，et al. Mechanisms of tetra- [36] HUNT T L，TZANIS E，BAI S，et al. The effect of vera‐
cycline resistance：plasmid-mediated tigecycline resistance pamil，a P-gp inhibitor，on the pharmacokinetics，safety，
[J]. Asian J Ecotoxicol，2022，17（4）：122-140. and tolerability of omadacycline in healthy adults：a phase
[24] MOORE I F，HUGHES D W，WRIGHT G D. Tigecycline Ⅰ ，open-label，single-sequence study[J]. Eur J Drug
is modified by the flavin-dependent monooxygenase TetX Metab Pharmacokinet，2021，46（1）：85-92.
[J]. Biochemistry，2005，44（35）：11829-11835. [37] STETS R，POPESCU M，GONONG J R，et al. Omadacy‐
[25] CHEN C，CUI C Y，ZHANG Y，et al. Emergence of
cline for community-acquired bacterial pneumonia[J]. N
mobile tigecycline resistance mechanism in Escherichia Engl J Med，2019，380（6）：517-527.
coli strains from migratory birds in China[J]. Emerg [38] LIN F，HE R，YU B，et al. Omadacycline for treatment of
Microbes Infect，2019，8（1）：1219-1222.
acute bacterial infections：a meta-analysis of phase Ⅱ/Ⅲ
[26] HE T，WANG R，LIU D J，et al. Emergence of plasmid- trials[J]. BMC Infect Dis，2023，23（1）：232.
mediated high-level tigecycline resistance genes in animals [39] 史海燕，胡英，黄建荣，等. 奥马环素对比美罗培南联合
and humans[J]. Nat Microbiol，2019，4（9）：1450-1456.
利奈唑胺治疗肺部感染：一项真实世界队列研究[J]. 中
[27] TANAKA S K，VILLANO S. In vitro and in vivo assess‐ 华临床感染病杂志，2023，16（3）：210-214.
ments of cardiovascular effects with omadacycline[J]. SHI H Y，HU Y，HUANG J R，et al. Comparison of omada-
Antimicrob Agents Chemother，2016，60（9）：5247-5253.
[28] GOTFRIED M H，HORN K，GARRITY-RYAN L，et al. cycline and meropenem plus linezolid in treatment of
pulmonary infection：a real-world cohort study[J]. Chin J
Comparison of omadacycline and tigecycline pharmacoki‐
netics in the plasma，epithelial lining fluid，and alveolar Clin Infect Dis，2023，16（3）：210-214.
cells of healthy adult subjects[J]. Antimicrob Agents Che‐ [40] 程文斌，陈晔. 奥马环素治疗鹦鹉热衣原体肺炎1例[J].
中国现代医生，2023，61（18）：140-142.
mother，2017，61（9）：e01117-e01135.
[29] BUNDRANT L A，TZANIS E，GARRITY-RYAN L，et al. CHENG W B，CHEN Y. A case of pneumonia treated with
Safety and pharmacokinetics of the aminomethylcycline omacycline[J]. China Mod Dr，2023，61（18）：140-142.
[41] FANG C Q，XU L M，TAN J R，et al. Omadacycline for
antibiotic omadacycline administered to healthy subjects
in oral multiple-dose regimens[J]. Antimicrob Agents Che‐ the treatment of severe Chlamydia psittaci pneumonia
mother，2018，62（2）：e01417-e01487. complicated with multiple organ failure：a case report[J].
[30] TZANIS E，MANLEY A，VILLANO S，et al. Effect of Infect Drug Resist，2022，15：5831-5838.
[42] WANG J，DONG S Y，FANG M J，et al. Omadacycline
food on the bioavailability of omadacycline in healthy par‐
ticipants[J]. J Clin Pharmacol，2017，57（3）：321-327. for the treatment of severe Chlamydia psittaci pneumonia
[31] RODVOLD K A，PAI M P. Pharmacokinetics and pharma‐ complicated with guillain-barre syndrome[J]. Infect Drug
codynamics of oral and intravenous omadacycline[J]. Clin Resist，2024，17：81-87.
Infect Dis，2019，69（Suppl. 1）：S16-S22. [43] XU L M，FANG C Q. Case report：omadacycline in the
[32] TANAKA S K，TZANIS E，VILLANO S. Effect of age treatment of macrolide-unresponsive Mycoplasma pneu‐
and gender on the pharmacokinetics of oral and Ⅳ omada‐ moniae pneumonia in an adolescent patient[J]. Front Cell
cycline，a new class of aminomethylcyclines[C]//Euro‐ Infect Microbiol，2023，13：1244398.
pean Society of Clinical Microbiology and Infectious Dis‐ （收稿日期：2024-04-24 修回日期：2024-07-28）
（编辑：舒安琴）
eases. Program and Abstracts of the 26th European Con‐

· 2576 · China Pharmacy 2024 Vol. 35 No. 20 中国药房 2024年第35卷第20期